| Literature DB >> 30667332 |
Jeffrey D Rudie1, Andreas M Rauschecker1, R Nick Bryan1, Christos Davatzikos1, Suyash Mohan1.
Abstract
Due to the exponential growth of computational algorithms, artificial intelligence (AI) methods are poised to improve the precision of diagnostic and therapeutic methods in medicine. The field of radiomics in neuro-oncology has been and will likely continue to be at the forefront of this revolution. A variety of AI methods applied to conventional and advanced neuro-oncology MRI data can already delineate infiltrating margins of diffuse gliomas, differentiate pseudoprogression from true progression, and predict recurrence and survival better than methods used in daily clinical practice. Radiogenomics will also advance our understanding of cancer biology, allowing noninvasive sampling of the molecular environment with high spatial resolution and providing a systems-level understanding of underlying heterogeneous cellular and molecular processes. By providing in vivo markers of spatial and molecular heterogeneity, these AI-based radiomic and radiogenomic tools have the potential to stratify patients into more precise initial diagnostic and therapeutic pathways and enable better dynamic treatment monitoring in this era of personalized medicine. Although substantial challenges remain, radiologic practice is set to change considerably as AI technology is further developed and validated for clinical use. © RSNA, 2019.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30667332 PMCID: PMC6389268 DOI: 10.1148/radiol.2018181928
Source DB: PubMed Journal: Radiology ISSN: 0033-8419 Impact factor: 11.105